NYSE - Nasdaq Real Time Price USD

Pfizer Inc. (PFE)

Compare
26.51 -0.21 (-0.78%)
As of 12:01 PM EST. Market Open.
Loading Chart for PFE
DELL
  • Previous Close 26.72
  • Open 26.74
  • Bid 26.50 x 29200
  • Ask 26.51 x 2900
  • Day's Range 26.42 - 26.85
  • 52 Week Range 25.20 - 31.54
  • Volume 13,448,306
  • Avg. Volume 33,406,189
  • Market Cap (intraday) 150.238B
  • Beta (5Y Monthly) 0.62
  • PE Ratio (TTM) 35.35
  • EPS (TTM) 0.75
  • Earnings Date Jan 28, 2025 - Feb 3, 2025
  • Forward Dividend & Yield 1.68 (6.29%)
  • Ex-Dividend Date Nov 8, 2024
  • 1y Target Est 32.88

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands. It also provides medicines and vaccines in various therapeutic areas, such as biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Litfulo, Velsipity, and Cibinqo brands; amyloidosis, hemophilia, endocrine diseases, and sickle cell disease under the Vyndaqel family, Oxbryta, BeneFIX, Somavert, Ngenla, and Genotropin brands; sterile injectable and anti-infective medicines under the Sulperazon, Medrol, Zavicefta, Zithromax, and Panzyga brands; and biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Inlyta, Bosulif, Mektovi, Padcev, Adcetris, Talzenna, Tukysa, Elrexfio, Tivdak, Lorbrena, and Braftovi brands. In addition, the company involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, individual provider offices, retail pharmacies, and integrated delivery systems. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Merck KGaA; and BioNTech SE, as well as has strategic clinical collaboration with Acepodia Inc. for the development of antibody-cell conjugation-based cell therapies in autoimmune diseases. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

www.pfizer.com

88,000

Full Time Employees

December 31

Fiscal Year Ends

Recent News: PFE

View More

Performance Overview: PFE

Trailing total returns as of 11/14/2024, which may include dividends or other distributions. Benchmark is

.

YTD Return

PFE
2.29%
S&P 500
25.15%

1-Year Return

PFE
2.93%
S&P 500
35.31%

3-Year Return

PFE
38.94%
S&P 500
27.47%

5-Year Return

PFE
5.43%
S&P 500
92.93%

Compare To: PFE

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: PFE

View More

Valuation Measures

Annual
As of 11/13/2024
  • Market Cap

    151.42B

  • Enterprise Value

    208.09B

  • Trailing P/E

    35.63

  • Forward P/E

    8.97

  • PEG Ratio (5yr expected)

    0.19

  • Price/Sales (ttm)

    2.55

  • Price/Book (mrq)

    1.64

  • Enterprise Value/Revenue

    3.50

  • Enterprise Value/EBITDA

    15.04

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    7.16%

  • Return on Assets (ttm)

    3.31%

  • Return on Equity (ttm)

    4.54%

  • Revenue (ttm)

    59.38B

  • Net Income Avi to Common (ttm)

    4.27B

  • Diluted EPS (ttm)

    0.75

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    9.95B

  • Total Debt/Equity (mrq)

    73.41%

  • Levered Free Cash Flow (ttm)

    11.42B

Research Analysis: PFE

View More

Earnings Per Share

Consensus EPS
 

Revenue vs. Earnings

Revenue 17.7B
Earnings 4.46B
Q4'23
Q1'24
Q2'24
Q3'24
0
5B
10B
15B
 

Analyst Recommendations

  • Strong Buy
  • Buy
  • Hold
  • Underperform
  • Sell
 

Analyst Price Targets

27.00
32.88 Average
26.51 Current
45.00 High
 

Company Insights: PFE

Research Reports: PFE

View More
  • Biopharma Election Impact: Potential Reduced IRA Headwind but Unpredictable Challenges

    Pfizer is one of the world's largest pharmaceutical firms, with annual sales close to $50 billion (excluding covid-19-related product sales). While it historically sold many types of healthcare products and chemicals, now prescription drugs and vaccines account for the majority of sales. Top sellers include pneumococcal vaccine Prevnar 13, cancer drug Ibrance, and cardiovascular treatment Eliquis. Pfizer sells these products globally, with international sales representing close to 50% of total sales. Within international sales, emerging markets are a major contributor.

    Rating
    Price Target
     
  • Pfizer Earnings: Maintaining Our Valuation as Management Pressed for Evidence of Productivity

    Pfizer is one of the world's largest pharmaceutical firms, with annual sales close to $50 billion (excluding covid-19-related product sales). While it historically sold many types of healthcare products and chemicals, now prescription drugs and vaccines account for the majority of sales. Top sellers include pneumococcal vaccine Prevnar 13, cancer drug Ibrance, and cardiovascular treatment Eliquis. Pfizer sells these products globally, with international sales representing close to 50% of total sales. Within international sales, emerging markets are a major contributor.

    Rating
    Price Target
     
  • Daily – Vickers Top Buyers & Sellers for 11/01/2024

    The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.

     
  • COVID products drive 3Q24 beat on EPS

    Pfizer is a leading developer and manufacturer of pharmaceuticals and biotech drugs. Its products include oncology and immunology drugs, treatments for rare diseases, and vaccines.

    Rating
    Price Target
     

Top Analysts: PFE

View More

Overall Score

Cantor Fitzgerald 46/100
Latest Rating
Overweight
 

Direction Score

BMO Capital 42/100
Latest Rating
Outperform
 

Price Score

Truist Securities 100/100
Latest Rating
Buy
 

People Also Watch